PATENT CLAIM ANALYSIS

Application Number: 16109974
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "171000"]

Abstract:
An implant comprising testosterone or an ester thereof and an aromatase inhibitor; the aromatase inhibitor may be selected from the group consisting of anastrozole, letrozole, and exemestane. In one embodiment the implant is a sustained release, subcutaneous implant. Also disclosed are therapies for patients with symptoms of relative androgen deficiency, breast cancer survivors and other therapies in which testosterone is indicated but elevated estradiol levels are avoided.

Claim (Index 1):
A method of treating a patient in need of testosterone therapy comprising administering to the patient at least one implant comprising a mixture of an amount of testosterone or an ester thereof and an amount of aromatase inhibitor in a weight ratio of testosterone or an ester thereof to aromatase inhibitor of 5:1 to 30:1, wherein the mixture forms a single implant with continuous delivery and zero order release of the testosterone or ester thereof and the aromatase inhibitor for a period of at least 30 days.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 96.0
- Lexical Diversity: 1.33929
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15248556', '15520278', '16055588', '13354103', '14853130']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7555605595766799
- 35 USC 102 Novelty (BERT): 0.5658623191009293
- Combined Prediction Score: 0.7365907355291048
- Mean Citation Score: 304.3221020000001
- Max Citation Score: 436.45276
- Similarity Product: 407.5014107909966

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test